Trial | NCT03542955  Report issue

Title

Pulse Shortwave Therapy in Cervical Osteoarthritis
The Efficacy/Safety Profile Of Pulsed Shortwave Therapy in Cervical Osteoarthritis: A Comparison Study Against Etoricoxib

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    etoricoxib ...

  • Study Participants

    180
The ActiPatch is an FDA cleared pain therapy device that uses pulsed shortwaves to interrupt pain signals at the nerve. 200 patients will be randomized and divided into an ActiPatch treatment group and comparison analgesic drug therapy group . Subjects will be assessed with the Neck Disability Index (NDI) at baseline and at four weeks and VAS scores will be recorded in order to determine the efficacy of the ActiPatch device compared to Etoricoxib. Cervical osteoarthritis causes chronic neck pain which could potentially be alleviated by the ActiPatch without the use of medication.
Cervical Osteoarthritis causes chronic pain in the neck due to the discs of the spine breaking down, losing fluid, and becoming stiffer over time. As obesity and age increase, the likelihood of cervical osteoarthritis increases as well. When the pain caused by the broken down discs becomes severe, it may result in a loss of mobility in the neck region. Chronic neck pain has a serious impact on not only quality of life, but can also negatively affect a persons ability to lead a healthy active lifestyle. Standard analgesic therapy it limited in efficacy and can result in serious adverse effects specially with long term use.
Study Started
May 01
2018
Primary Completion
Jul 30
2019
Study Completion
Jul 30
2019
Last Update
Aug 30
2019

Device ActiPatch

A Pulsed Shortwave Therapy Device

  • Other names: pulsed shortwave therapy

Drug Etoricoxib 60 mg

nonsteroidal anti-inflammatory drug used as standard therapy

  • Other names: analgesic

ActiPatch Group Active Comparator

Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.

Control Group Placebo Comparator

Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.

Criteria 

Inclusion Criteria:

Chronic Neck Pain of > 2 months
Cervical Osteoarthritis - Radiological Evidence
Males & females
Age: 30-60 years

Exclusion Criteria:

Neck Pain <2 months
Pregnancy
Irreversible neck injury
Congenital Neurological/Muscular Diseases
Osteo-articular Disorders
Auto-immune Diseases
Osteoporosis
Hematological Diseases (Thalassemia/Sickle Cell Anemia)
Cancer
Contra-indication to Etoricoxib 60 mg
Age <30 or >60 years
No Results Posted